首页> 外文OA文献 >Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism
【2h】

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism

机译:蛋白酶体和I类HDaC抑制剂的组合通过HDaC6非依赖性ER应激诱导机制诱导NpC细胞凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The current paradigm stipulates that inhibition of histone deacetylase (HDAC) 6 is essential for the combinatorial effect of proteasome and HDAC inhibitors for the treatment of cancers. Our study aims to investigate the effect of combining different class I HDAC inhibitors (without HDAC6 action) with a proteasome inhibitor on apoptosis of nasopharyngeal carcinoma (NPC). We found that combination of a proteasome inhibitor, bortezomib, and several class I HDAC inhibitors, including MS-275, apicidin and romidepsin, potently induced killing of NPC cells both in vitro and in vivo. Among the drug pairs, combination of bortezomib and romidepsin (bort/romidepsin) was the most potent and could induce apoptosis at low nanomolar concentrations. The apoptosis of NPC cells was reactive oxygen species (ROS)- and caspase-dependent but was independent of HDAC6 inhibition. Of note, bort/romidepsin might directly suppress the formation of aggresome through the downregulation of c-myc. In addition, two markers of endoplasmic reticulum (ER) stress-induced apoptosis, ATF-4 and CHOP/GADD153, were upregulated, whereas a specific inhibitor of caspase-4 (an initiator of ER stress-induced apoptosis) could suppress the apoptosis. When ROS level in the NPC cells was reduced to the untreated level, ER stress-induced caspase activation was abrogated. Collectively, our data demonstrate a model of synergism between proteasome and class I HDAC inhibitors in the induction of ROS-dependent ER stress-induced apoptosis of NPC cells, independent of HDAC6 inhibition, and provide the rationale to combine the more specific and potent class I HDAC inhibitors with proteasome inhibitors for the treatment of cancers.
机译:当前的范例规定,抑制组蛋白脱乙酰基酶(HDAC)6对于蛋白酶体和HDAC抑制剂对癌症的治疗具有至关重要的作用。我们的研究旨在研究将不同的I类HDAC抑制剂(无HDAC6作用)与蛋白酶体抑制剂联合使用对鼻咽癌(NPC)细胞凋亡的影响。我们发现,蛋白酶体抑制剂,硼替佐米和几种I类HDAC抑制剂(包括MS-275,阿皮素和罗米地辛)的组合在体外和体内均能有效诱导NPC细胞的杀伤。在这些药物对中,硼替佐米和罗米地辛的组合(bort / romidepsin)是最有效的,并且可以在低纳摩尔浓度下诱导细胞凋亡。 NPC细胞的凋亡是活性氧(ROS)和caspase依赖性的,但与HDAC6抑制无关。值得注意的是,硼酸/磷酸蛋白酶可能通过下调c-myc直接抑制聚集体的形成。此外,内质网(ER)应激诱导的凋亡的两个标志物ATF-4和CHOP / GADD153被上调,而caspase-4的特异性抑制剂(ER应激诱导的凋亡的引发剂)可以抑制凋亡。当NPC细胞中的ROS降低至未处理水平时,ER应激诱导的caspase激活被取消。总的来说,我们的数据证明了蛋白酶体和I类HDAC抑制剂在ROS依赖性ER应激诱导的NPC细胞凋亡诱导中的协同作用模型,独立于HDAC6抑制,并提供了结合更特异性和有效I类的原理HDAC抑制剂与蛋白酶体抑制剂一起用于治疗癌症。

著录项

  • 作者

    Hui, KF; Chiang, AKS;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号